Catalyst Calendar

Tue, Aug 25, 2026

1 updates

1:00 AM

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027 CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in

molecularpartners.com

Thu, Jul 16, 2026

1 updates

MOLN

1:00 AM

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing Data update expected in 2027, with trial completion in 2028 Trial-in-progress poster to be presented at ESMO 2026 in October ZURICH-SCHLIEREN, Switzerland and CONCORD,

Trial Start • Phase 2Trial initiation Thu, Jul 16, 2026molecularpartners.com

Wed, Jul 15, 2026

1 updates

MOLN

1:00 AM

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins’ ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026

molecularpartners.com